Vilon Peptide (Lys-Glu): What the Published Research Reports

Vilon is one of the few Khavinson bioregulators with animal studies naming it directly — spontaneous tumour inhibition, lifespan, induced carcinogenesis models and gene expression. A citation-by-citation summary, with the limits stated.

vilon bioregulator khavinson Lys-Glu dipeptide thymic gene expression

Key Research Findings

  • Vilon is the synthetic dipeptide Lys-Glu, one of the shortest compounds in the Khavinson bioregulator family, associated with thymic and immune tissue.
  • Unlike most of the family it has animal studies naming it directly: spontaneous tumour inhibition and increased lifespan in mice (PMID 10944717).
  • Two induced-carcinogenesis models report inhibitory effects — rat bladder tumours (PMID 11586406) and DMH-induced neoplasia (PMID 16308980).
  • A DNA-microarray study of Vilon and Epithalon in mouse heart tests the transcriptional-regulation hypothesis directly (PMID 12360356).
  • The literature is concentrated in one research group and largely Russian-language; independent replication is limited.
  • No controlled human programme exists, so no dosage figure is published for any context.

What Vilon Is

Vilon is a synthetic dipeptide, Lys-Glu, and one of the shortest members of the peptide bioregulator family. At two residues it sits at the extreme short end even within a family defined by brevity, and it is associated in the published literature with thymic and immune tissue.

It also has something most compounds in this family lack: a body of published animal work that names it directly, including long-term carcinogenesis studies. That makes it one of the few bioregulators where specific claims can be traced to specific experiments.

Research use only. Vilon is supplied for laboratory research. It is not for human or veterinary use, holds no marketing authorisation in any jurisdiction, and nothing below is guidance for administration.

What the Published Studies Report

Spontaneous tumour development and lifespan in mice

The most cited work reports that the synthetic dipeptide inhibited growth of spontaneous tumours and increased lifespan in mice (Khavinson et al., Dokl Biol Sci 2000, PMID 10944717). This is a whole-animal, long-duration design rather than a cell-culture endpoint, which is why it anchors most later discussion of the compound.

Induced carcinogenesis models

Two independent reports from the same group extend the observation to chemically induced models: an inhibitory effect on development of induced urinary bladder tumours in rats (Pliss et al., Bull Exp Biol Med 2001, PMID 11586406) and an effect on 1,2-dimethylhydrazine-induced neoplasia (Pliss et al., Vopr Onkol 2005, PMID 16308980).

Read these as what they are: rodent chemoprevention models in a specific induction paradigm. They describe an effect on tumour development under experimental induction. They do not establish an effect in any other species or context.

Gene expression

The mechanistic link to the wider family comes from a DNA-microarray study examining the effects of Vilon and Epithalon on gene expression in mouse heart (Anisimov et al., Bull Exp Biol Med 2002, PMID 12360356). It is one of the earlier attempts to test the transcriptional-regulation hypothesis directly rather than infer it from phenotype, and it is why Vilon is usually discussed alongside Epithalon.

Immune and haemostatic parameters

A later report examined immune status and coagulation haemostasis across age groups in diabetes mellitus (Kuznik et al., Adv Gerontol 2007, PMID 18306698). This is the study most often cited for the compound's thymic and immune association.

Reading the Evidence Honestly

Three qualifications belong with every summary above.

The literature is concentrated. Most of it comes from the St Petersburg group and its collaborators, and much appears in Russian-language journals. Concentration is not the same as unreliability, but it means independent replication is limited and should not be assumed.

The models are animal models. Rodent chemoprevention and lifespan designs are informative for mechanism generation. They do not transfer to other species without work that has not been done.

There is no established amount for any use. No controlled human programme exists, so there is no published figure to report. Where the literature reports nothing for a context, that absence is the finding rather than a gap to fill by analogy with a related peptide.

Structure and Laboratory Handling

  • Sequence. Lys-Glu — a dipeptide, among the shortest compounds in the family.
  • Form. Lyophilised powder. Store the sealed vial at −20 °C, protected from light.
  • Reconstitution. Introduce bacteriostatic water down the vial wall rather than onto the powder cake. Do not shake — peptide solutions foam readily and agitation promotes aggregation.
  • After reconstitution. Refrigerate at 2–8 °C. Reconstituted solution has materially shorter working stability than the lyophilised powder.
  • Concentration. Vial mass divided by diluent volume; our reconstitution calculator performs the arithmetic and converts to insulin-syringe units.

Where Vilon Sits in the Family

Vilon is the thymic and immune member of the bioregulator set. Thymalin shares that association and has its own literature; Epithalon is the pineal and telomere-associated member it is most often studied beside. For the family as a whole — the proposed gene-expression mechanism, the cytomax versus cytogen distinction, and the full catalog by physiological system — see our peptide bioregulator overview.

For background on handling lyophilised material see lyophilised peptides: what researchers need to know, and for the meaning of the research-use designation see what “for research use only” means.

Frequently Asked Questions

What is Vilon peptide?

Vilon is a synthetic dipeptide with the sequence Lys-Glu, one of the shortest members of the Khavinson peptide bioregulator family. It is associated in the published literature with thymic and immune tissue, and unlike most compounds in the family it has animal studies that name it directly, including long-term carcinogenesis and lifespan work.

What does the research on Vilon actually show?

Published animal work reports inhibition of spontaneous tumour growth and increased lifespan in mice (PMID 10944717), inhibitory effects in induced rat bladder tumour models (PMID 11586406) and in 1,2-dimethylhydrazine-induced neoplasia (PMID 16308980), plus gene-expression effects in mouse heart measured by DNA microarray (PMID 12360356). All are animal models.

Is there an established Vilon dosage?

No. There is no controlled human programme for Vilon and therefore no published figure to report for any population or context. Amounts circulating in non-clinical discussion are not traceable to controlled trials.

How is Vilon different from Thymalin?

Both are associated with thymic and immune tissue, but they are different molecules with separate literatures. Vilon is the synthetic dipeptide Lys-Glu; Thymalin is a distinct preparation with its own published work. Findings reported for one do not transfer to the other.

Is Vilon approved for any use?

No. Vilon holds no marketing authorisation in any jurisdiction. Material supplied by AminoCore Research is intended for laboratory research only, not for human or veterinary use.

How is Vilon stored and reconstituted?

Store the sealed lyophilised vial at −20 °C protected from light. Introduce bacteriostatic water down the vial wall rather than onto the powder cake and do not shake, since agitation causes foaming and promotes aggregation. Refrigerate reconstituted solution at 2–8 °C.

References

  1. Khavinson VKh, Anisimov VN, Zavarzina NY, Zabezhinskii MA, Zimina OA, Popovich IG, et al.. A synthetic dipeptide vilon (L-Lys-L-Glu) inhibits growth of spontaneous tumors and increases life span of mice Doklady Biological Sciences (2000)
  2. Pliss GB, Mel'nikov AS, Malinin VV, Khavinson VKh. Inhibitory effect of peptide vilon on the development of induced rat urinary bladder tumors in rats Bulletin of Experimental Biology and Medicine (2001)
  3. Pliss GB, Mel'nikov AS, Malinin VV, Khavinson VKh. The effect of vilon (Lys-Glu) on 1,2-dimethylhydrazine-induced neoplasia Voprosy Onkologii (2005)
  4. Anisimov SV, Khavinson VKh, Anisimov VN. Studies of the effects of Vilon and Epithalon on gene expression in mouse heart using DNA-microarray technology Bulletin of Experimental Biology and Medicine (2002)
  5. Kuznik BI, Morozov VG, Khavinson VKh, Vitkovsky YA. Effect of vilon on the immunity status and coagulation hemostasis in patients of different age with diabetes mellitus Advances in Gerontology (2007)
Research Use Only: This content is intended for laboratory and scientific research purposes only. It is not intended for human use, medical advice, diagnosis, or treatment. All compounds discussed are for in vitro and preclinical research contexts.